Piper Sandler Reiterates Overweight on Skye Bioscience, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $20 price target.
September 20, 2024 | 5:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on Skye Bioscience, maintaining a $20 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a $20 price target by Piper Sandler suggests a positive outlook for Skye Bioscience, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100